The Case for Early Chemotherapy for the Treatment of Metastatic Disease

Journal of Urology

Volumn 176, Issue 6 SUPPL., 2006, Pages

  Lucas, Aimee ^a   Petrylak, Daniel P ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

docetaxel; drug therapy; neoplasm metastasis; prostate; prostatic cancer

Indexed keywords

DOCETAXEL; MITOXANTRONE; PREDNISONE;

ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; STANDARDIZATION; THEORETICAL STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750438101     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.077     Document Type: Article

References (18)

1. Loblaw D.A., Mendelson D.S., Talcott J.A., Virgo K.S., Somerfield M.R., Ben-Josef E., et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 (2004) 2927
2. Tannock I., Gospodarowicz M., Meakin W., Panzarella T., Stewart L., and Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7 (1989) 590
3. Kantoff P.W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 17 (1999) 2506
4. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756
5. Petrylak D.P., Tangen C.M., Hussain M.H.A., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
6. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
7. Oltvaim Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609
8. Perlman H., Zhang X., Chen M.-H., Walsh K., and Buttyan R. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 6 (1999) 48
9. Eigl B.J.C., Eggener S.E., Baybik J., ettinger S., Chi K.N., Nelson C., et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 11 (2005) 4905
10. Tang Y., Khan M.A., Goloubeva O., Lee D.I., Jelovac D., Brodie A.M., et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 12 (2006) 169
11. Hussain A., Dawson N., Amin P., Engstrom C., Dorsey B., Siegel E., et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 23 (2005) 2789
12. Berry W., Dakhil S., Modiano M., Gregurich M., and Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168 (2002) 2439
13. Petrylak D.P., Scher H.I., Li Z., Myers C.E., and Geller N.L. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70 (1992) 2870
14. Hussain M., Wolf M., Marshall E., Crawford E.D., and Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12 (1994) 1868
15. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232
16. George D.J., Halabi S., Shepard T.F., Sanford B., Vogelzang N.J., Small E.J., et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480. Clin Cancer Res 11 (2005) 1815
17. Taplin M.E., George D.J., Halabi S., Sanford B., Febbo P.G., Hennessy K.T., et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66 (2005) 386
18. Walczak J.R., and Carducci M.A. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), intergroup/clinical trials support unit study. Urology 62 (2003) 141